Pilot Study of Maintenance Therapy With Intravenous AMANTADINE

Maintenance Therapy of Intravenous Amantadine in Patients With Idiopathic Parkinson Disease Who Are Not Optimally Treated With Anti Parkinson Medications

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01190553

Enrollment

Registered

2010-08-27

Start date

2010-11-30

Completion date

2012-06-30

Last updated

2010-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson Disease

Keywords

amantadine, parkinson disease, dyskinesia

Brief summary

This is a pilot study for Maintenance Intravenous Treatment with AMANTADINE in patient with PARKINSON'S Disease who are not well balanced with medical treatment.

Interventions

DRUGAmantadine

Initiation: IV amantadine 200mg/500ml \* 1/d for 3 days Maintenance: IV amantadine 200mg/500ml once per 6 weeks for 6 months

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

30 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Patients with idiopathic Parkinson disease * Age\<80 * Patients with no motor improvement under optimal treatment with anti parkinson medications * Patients with moderate to severe dyskinesias * Patients with PD with side effects who can not tolerate anti parkinson medications

Exclusion criteria

* Age\>80 * Patients with Parkinson syndromes, vascular parkinsonism or drug-induced parkinsonism * Patients with PD who developed adverse reactions to oral amantadine * Contraindication of amantadine treatment

Design outcomes

Primary

Measure	Time frame
Improvement of UPDRS scores after 6 months of treatment	6 months
Improvement of dyskinesias score.	6 months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026